INTRAOCULAR DRUG DELIVERY DEVICE AND ASSOCIATED METHODS

• US 20120089113A1
• Filed: 08/16/2011
• Published: 04/12/2012
• Est. Priority Date: 05/12/2008
• Status: Active Grant

• Current Assignee: University of Utah Research Foundation (State of Utah)
• Original Assignee: University of Utah Research Foundation (State of Utah)
• Inventors: Gale, Bruce K., Ambati, Balamurali K.
• Granted Patent: US 9,095,404 B2
• Time in Patent Office: Days
• US Class Current: 604/500
• CPC Class Codes: A61F 9/0017 implantable in, or in contact with, the eye, e.g. ocular inserts
• CPC Class Codes: A61K 9/0051 Ocular inserts, ocular implants

Abstract

Devices, systems, and methods for delivery of an active agent into the eye of a subject can include an ocular active agent delivery device (40) having an active agent reservoir (44) disposed in an annular body (42), the annular body (42) being configured to fit inside of a lens capsule and at least partially encircling a line of sight of an intraocular lens within the lens capsule.

Claims

1. An ocular active agent delivery device, comprising:

an active agent reservoir disposed in an annular body, said annular body at least partially encircling a line of sight of an intraocular lens within the lens capsule.

2. The device of claim 1, wherein the active agent reservoir contains at least one of bevacizumab, timolol, latanoprost, brimonidine, nepafenac, ranibizumab, antibiotic, prednisolone, fluocinolide, anti-VEGF aptamers, anti-VEGF Fab fragments, and integrin antagonists.

3. The device of claim 1, wherein the annular body is formed of an active agent matrix having the active agent dispersed therein.

4. The device of claim 3, wherein the active agent matrix is capable of functioning as a valve to allow filling of the active agent reservoir with the active agent and as a semipermeable membrane to allow diffusion of the active agent from the active agent matrix.

5. The device of claim 4, wherein the valve is a resealable elastomeric material.

6. The device of claim 3, wherein the active agent matrix is a biodegradable material.

7. The device of claim 1, wherein the annular body further includes:

a semipermeable membrane operatively associated with the active agent reservoir as a portion of the annular body, said semipermeable membrane allowing diffusion of the active agent from the active agent reservoir over an extended period of time; and

a valve operatively coupled to the active agent reservoir at a dedicated valve location along the annular body, said valve being configured to allow filling of the active agent reservoir with the active agent.

8. The device of claim 1, wherein the annular body forms an incomplete circle.

9. The device of claim 1, wherein the annular body includes at least two bulbous portions.

10. The device of claim 1, wherein the annular body further includes at least one manipulation handle to allow secure handling of the device during implantation or subsequent removal of the device from an eye.

11. The device of claim 1, further comprising at least one secondary active agent reservoir disposed within the annular body.

12. The device of claim 1, further comprising an osmotic pump operatively coupled to the active agent reservoir, said osmotic pump being configured to facilitate delivery of the active agent from the active agent reservoir.

13. The device of claim 1, further comprising a biosensor configured to detect at least one of levels of drug within the device to indicate need for refill, intraocular pressure, and intraocular markers of disease.

14. A method of treating an eye condition, comprising administering an active agent to the eye using the device of claim 1 by associating the device with an intraocular lens of the eye such that the annular body at least partially encircles a line of sight of the intraocular lens.

15. The method of claim 14, wherein the eye condition is at least one of AMD, glaucoma, diabetic retinopathy, Retinopathy of Prematurity, uveitis, corneal transplant rejection, capsular fibrosis, posterior capsule opacification, retinal vein occlusions, cataracts, and infection.

16. The method of claim 14, wherein the active agent includes at least one of bevacizumab, timolol, latanoprost, brimonidine, nepafenac, ranibizumab, antibiotic, prednisolone, fluocinolide, anti-VEGF aptamers, anti-VEGF Fab fragments, and integrin antagonists

17. The device of claim 1, wherein the annular body is configured to fit inside a lens capsule.